Welcome to join our lunchtime webinar on April 10th on early detection of dementia.
We welcome Professor Henrik Zetterberg , Professor of Neurochemistry, Chief Physician University of Gothenburg and Chair of the Alzheimer's Foundation Scientific Council.
In November, the EMA approved the appeal for the Alzheimer's disease drug Lecanemab. But what does this mean in practice? When will it reach clinical practice in Sweden and who will receive it? And how should Sweden think and act to identify who should have the drug in the first place and who may not be suitable candidates at all? If we can now identify incipient disease 15-20 years before it breaks out with symptoms, should everyone be tested? If not, how should we decide who should be tested early?
Henrik is leading the development of new generation diagnostics using blood biomarkers. In this lecture, he will take us through the diagnostics of the future, the treatments of the future and the challenges we will soon face...
Time of event: Thursday, April 10, 12-13
You can register at the following link: https://forms.gle/ksjFjEC6cGjCn5Zi6
In the days before the webinar, you will receive an email confirmation with a video link (check your spam folder, it sometimes goes there).
Feel free to spread the invitation to others who you think might be interested in participating.
A warm welcome!
